News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

November 13, 2020 Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
November 11, 2020 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 5, 2020 Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting
November 2, 2020 Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
October 27, 2020 Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
October 19, 2020 Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)
October 15, 2020 Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity
October 9, 2020 Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week
October 5, 2020 Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need
October 3, 2020 Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)